Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Inks World-First Pact With NHS England For Inclisiran

Tackling Challenge Of Cardiovascular Disease

Executive Summary

The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.

You may also be interested in...



Six Questions For Novartis CEO Narasimhan

Novartis CEO Vas Narasimhan outlines how the company is progressing data science and digital transformation across operations, including plans to use predictive analytics to forecast production supply chain runs. The Swiss firm is also monitoring the evolving coronavirus situation closely but has safety stocks for its key products and innovative medicine portfolio and is "okay" for now.

In Vivo's Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.

Is NICE’s Pricing Influence On The Wane?

The pricing of medicines may appear as a mystery to many; theories range from what the market will bear to prices being based on value. The Pink Sheet examines the role of two key players with influence in drug pricing in the UK – health technology assessment body NICE, which decides whether a product is value for money, and NHS England, which leads the tax-funded national health service in England and pays for new specialized drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel